Open trial of flutamide for treatment of obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 60, Issue 7, 1999, Pages 442-445

  Altemus, Margaret ^a   Greenberg, Benjamin D ^b   Keuler, David ^b   Jacobson, Karen R ^a   Murphy, Dennis L ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FLUTAMIDE;

ADULT; AGGRESSION; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SELF CONCEPT; SEXUAL FUNCTION; TREATMENT OUTCOME;

EID: 0032796589     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0704     Document Type: Article

References (42)

1. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:53-60
2. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308
3. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11:242-248
4. McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-184
5. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 1993;150:647-649
6. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993;150:819-821
7. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261-1264
8. Casas M, Alvarez E, Duro P, et al. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986;73:221-222
9. Leonard HL. Drug treatment of obsessive-compulsive disorder. In: Rapoport JL, ed. Obsessive-Compulsive Disorder in Children and Adolescents. Washington, DC: American Psychiatric Press; 1989:217-236
10. Ghadirian AM, Engelsmann F, Dhar V, et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995;37:369-375
11. Weiss M, Baerg E, Wisebord S, et al. The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. Can J Psychiatry 1995; 40:205-207
12. Chouinard G, Belanger MC, Beauclair L, et al. Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: a case report. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1067-1079
13. Nezeroglu F, Anemone R, Yaryura-Tobia J. Onset of obsessive-compulsive disorder in pregnancy. Am J Psychiatry 1992;149:947-950
14. Buttolph ML, Holland A. Obsessive compulsive disorder in pregnancy and childbirth. In: Jenike M, Baer L, Minichiello WE, eds. Obsessive-Compulsive Disorders: Theory and Management. Chicago, Ill: Year Book Medical Publishers; 1990
15. Rasmussen SA, Eisen JL. Epidemiology of obsessive compulsive disorder. J Clin Psychiatry 1990;51(2, suppl):10-13
16. Brodgen RN, Clissold SP. Flutamide: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 1989;38:185-203
17. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346:265-269
18. Stone NN, Clejan SJ. Response of prostate volume, prostate-specific antigen, and testosterone to flutamide in men with benign prostatic hyperplasia. J Andrology 1991;12:376-380
19. Cusan L, Dupont A, Belanger A, et al. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990;23:462-469
20. Neri R, Florance K, Koziol P, et al. A biological profile of a nonsteroidal antiandrogen, SCH13521 (4′-nitro-3′-trifluoromethylisobutyranilide). Endocrinology 1972;91:427-437
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
22. Spitzer RL, Williams JBW, Gibbon M, et al. Structured Clinical Interview for DSM-III-R (SCID). New York, NY: Biometric Research, New York State Psychiatric Institute; 1987
23. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. Arch Gen Psychiatry 1989;46:1006-1016
24. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
25. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
26. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service; 1971
27. Dominguez RA, Jacobson AF, de la Gandara J, et al. Drug response assessed by the Modified Maudsley Obsessive Compulsive Inventory. Psychopharmacol Bull 1989;25:215-218
28. Beck AT, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56: 893-897
29. Peterson BS, Leckman JF, Scahill L, et al. Steroid hormones and Tourette's syndrome: early experience with antiandrogen therapy. J Clin Psychopharmacol 1994;14:131-135
30. Pecins-Thompson M, Brown NA, Kohama SG, et al. Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. J Neurosci 1996;16:7021-7029
31. McQueen JK, Wilson H, Fink G. Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain. Brain Res Mol Brain Res 1997;45:13-23
32. Attali G, Weizman A, Gil-Ad I, et al. Opposite modulatory effects of ovarian hormones on rat brain dopamine and serotonin transporters. Brain Res 1997;756:153-159
33. 2A receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol 1995;54:15-20
34. Castner SA, Xiao L, Becker JB. Sex differences in striatal dopamine: in vivo microdialysis and behavioral studies. Brain Res 1993;610:127-134
35. 2 dopamine receptor binding. Brain Res 1994;637: 163-172
36. DeVries GJ, Wang Z, Bullock NA, et al. Sex differences in the effects of testosterone and its metabolites on vasopressin messenger RNA levels in the bed nucleus of the stria terminalis of rats. J Neurosci 1994;14: 1789-1794
37. Miller MA, DeVries GJ, al-Shamma HA, et al. Decline of vasopressin immunoreactivity and mRNA levels in the bed nucleus of the stria terminalis following castration. J Neurosci 1992;12:2881-2887
38. Altemus M, Pigott T, Kalogeras KT, et al. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:9-20
39. Altemus M, Swedo S, Leonard H, et al. Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry 1994;51:794-803
40. Debellis MD, Geracioti TD, Listwak SJ, et al. Fluoxetine reduces CSF CRH and AVP in major depression. Am J Psychiatry 1993;150:656-657
41. Altemus M, Cizza G, Gold PW. Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Res 1992;593:311-313
42. Karayiorgou M, Altemus M, Galke BL, et al. Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A 1997;94:4572-4575